Related Experiment Videos
XAS applied to pharmaceuticals: drug administration and bioavailability
I Nicolis1, P Deschamps, E Curis
1Laboratoire de Biomathématique, Faculté de Harmacie, Université Paris V, France. nicolis@pharmacie.univ-paris5.fr
Journal of Synchrotron Radiation
|August 22, 2001
Summary
Synchrotron X-ray absorption spectroscopy (XAS) applications are explored for hospital drug administration and bioavailability. XAS effectively analyzed nutrient interactions, copper-aminoacid complexes for Menkes disease, and an arsenic drug for leukemia, alongside hair trace element monitoring.
Area of Science:
- Materials Science
- Analytical Chemistry
- Medical Physics
Background:
- X-ray absorption spectroscopy (XAS) offers unique capabilities for analyzing elemental speciation and chemical states.
- Understanding drug bioavailability and nutrient interactions is crucial for effective therapeutic strategies in clinical settings.
- Advanced analytical techniques are needed to push the limits of sensitivity for complex biological and pharmaceutical samples.
Purpose of the Study:
- To demonstrate the practical applications of XAS in addressing hospital-related questions concerning drug administration and bioavailability.
- To investigate the bioavailability of zinc in parenteral nutrition solutions through its interactions with amino acids.
- To develop novel copper-aminoacid complexes for treating Menkes disease and characterize arsenic-based leukemia drugs.
Main Methods:
- X-ray absorption spectroscopy (XAS), including extended X-ray absorption fine structure (EXAFS) and X-ray absorption near edge structure (XANES), was employed.
- Analysis of binary and ternary copper-aminoacid complexes.
- X-ray fluorescence (XRF) excited by synchrotron radiation was used for trace element analysis in patient hair samples.
Main Results:
- XAS elucidated interactions between zinc and amino acids in parenteral nutrition, potentially affecting bioavailability.
- Characterization of copper-aminoacid complexes provides insights for Menkes disease drug development.
- The solution form of a novel arsenic-containing leukemia drug was successfully identified using EXAFS and XANES.
Conclusions:
- XAS is a powerful technique for investigating drug bioavailability and nutrient interactions in clinical contexts, even at sensitivity limits.
- The study highlights XAS's role in developing targeted therapies for genetic disorders like Menkes disease and for cancer treatment.
- Synchrotron-based XRF analysis of hair offers a valuable method for monitoring essential trace elements during patient therapy.